# Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)

> **NCT03560466** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 378 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Dupilumab (SAR231893/REGN668)
- **DRUG:** Asthma controller therapies (incl. prednisone/prednisolone)
- **DRUG:** Asthma reliever therapies

## Key facts

- **NCT ID:** NCT03560466
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-21
- **Primary completion:** 2025-04-01
- **Final completion:** 2025-04-01
- **Target enrollment:** 378 (ACTUAL)
- **Last updated:** 2025-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03560466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03560466, "Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03560466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*